newsfilter
← Latest News
GlobeNewswire·

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated